Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S356100, C548S373100, C548S375100, C548S376100
Reexamination Certificate
active
06964978
ABSTRACT:
The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
REFERENCES:
patent: 5466823 (1995-11-01), Talley et al.
patent: 5892053 (1999-04-01), Zhi et al.
patent: 6248745 (2001-06-01), Hamley et al.
patent: 6384034 (2002-05-01), Simitchieva et al.
patent: 0 147 171 (1985-07-01), None
patent: 98/19708 (1998-05-01), None
patent: WO 98/43980 (1998-10-01), None
patent: WO 00/32189 (2000-06-01), None
patent: WO 00/42021 (2000-07-01), None
patent: WO 00/66562 (2000-11-01), None
patent: WO 01/15664 (2001-03-01), None
Stavchansky et al: Bioavailability in Tablet Technology. In Pharmaceutical dosage forms, by Marcel Dekker, Inc. p 349-472, 1990.
Hageman Michael J.
He Xiaorong
Kararli Tugrul T.
Mackin Lesley A.
Miyake Patricia J.
Ashbrook Charles
Fitzsimmons Patricia K.
Pharmacia Corporation
Shameem Golam M M
LandOfFree
Solid-state form of celecoxib having enhanced bioavailability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solid-state form of celecoxib having enhanced bioavailability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid-state form of celecoxib having enhanced bioavailability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3507011